ImmunityBio

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy company ImmunityBio, Inc. (NASDAQ: IBRX), today announced the opening of a clinical trial to study ANKTIVA® (nogapendekin alfa inbakicept-pmln) together with the investigational AdHER2DC vaccine (autologous dendritic cells transduced with HER2 expressing adenovirus), in individuals with HER2-expressing endometrial cancer. It marks the latest trial involving ANKTIVA, the company's IL-15 superagonist immune enhancer, to evaluate ANKTIVA as an ag.

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

NEW YORK , July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

Amgen

Arcutis Biotherapeutics

Axsome Therapeutics

Madrigal Pharmaceuticals

Intellia Therapeutics

Vertex Pharmaceuticals

Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.

7 Biotech Stocks to Keep on Your Clinical Radar

GRAIL Inc

GlaxoSmithKline

Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.

3 Top Cancer Treatment Stocks to Buy Now

ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

IBRX has a short interest % of the float of 33%, superior to GME at 21%. Investors should keep an eye on it for short squeeze-fueled volatility. IBRX has positive catalysts on the horizon, such as the commercialization of Anktiva for bladder cancer and the FDA review of Anktiva for lung cancer. IBRX has an overleveraged balance sheet, but the billionaire "face" of the company, Patrick Soon-Shiong, will ensure it remains solvent. Any capital raises from him likely won't increase the float.

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the initial treatment of multiple patients in the United States to receive therapy with ANKTIVA® (nogapendekin alfa inbakicept-pmln), ImmunityBio's recently approved immunotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. ANKTIVA was approved by the U.S. Food and Drug Administration (FDA) on April 22, 2024 for the treatment of patients with B.

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

C3.ai

UnitedHealth Group

A short-squeeze stocks to buy are something investors need to watch out for. If investors believe that a stock's price will fall within a certain time frame, they will enter a short position.

3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions

Arbor Realty Trust

Medical Properties Trust

Trupanion

Upstart Holdings

In recent weeks, extreme volatility in specific stocks has resurged following the return of popular trader Keith Gill, also known as Roaring Kitty, to social media. After a nearly four-year hiatus, Gill disclosed a sizable stake in GameStop (NYSE: GME), reigniting interest in the stock.

These 5 stocks are potential short-squeeze candidates

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Off.

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

ImmunityBio's flagship product, Anktiva, has been launched in the market for the treatment of bladder cancer, with strong clinical data supporting its efficacy. The company is well-prepared for the launch, with a strong sales force, established distribution channels, and sufficient inventory. Analyst projections suggest significant growth for ImmunityBio, with the potential for Anktiva to become a blockbuster drug and drive the company's revenue in the coming years.

ImmunityBio: Anktiva's Launch Demands A Reassessment

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company's recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cancer research. Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific at ImmunityBio, discussed the breakin.

Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

EVgo

El Pollo Loco

There are several types of bargain stocks available to buy in the stock market. There are, of course, traditional bargain stocks with very low valuations and an average growth rate.

The 3 Best Bargain Stocks to Buy in May 2024

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for “fill finish” (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg ANKTIVA (nogapendekin alfa inbakicept-pmln). Coupled with the recent announcement of a partnership with the Serum Institute of India (SII) for BCG availability, this provides the Company with a significant initial supply of ANKTIVA for com.

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

MicroStrategy Incorporated

Rumble Inc

You'll get no argument from me that GameStop (NYSE: GME ) is one of the best meme stocks to sell. However, the video game retailer has been around a long time, suggesting it's not the worst of the meme stocks to sell.

Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), has signed an exclusive global arrangement with the Serum Institute of India, the world's largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG). The agreement covers the manufacturing of standard BCG (sBCG) that is currently approved for use outside the U.S., as well as a next-generation recombinant BCG (iBCG) undergoing testing, intended for use in combinati.

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

CULVER CITY, Calif.--(BUSINESS WIRE)--The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. (NASDAQ: IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors at the American Urological Association.

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva, its cancer drug. It has risen for two straight days and is now sitting at its highest level since September 2021.

What's going on with the ImmunityBio (IBRX) stock price?

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab) and standard-of-care chemotherapy to be discussed during the upcoming conference call. The results continue to reinforce ImmunityBio's belief in the unique mechanism of action of ANKTIVA (N-803, o.

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

FDA approved ImmunityBio, Inc.'s ANKTIVA for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The global bladder cancer market could reach $11.5 billion by 2032. Company also tends to evaluate the use of ANKTIVA towards other cancer indications such as acute myeloid leukemia and platinum-resistant ovarian cancer.

ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications

ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After dropping by over 6% in the regular session on Monday, it rebounded by over 20% in the extended session.

Here's why ImmunityBio (IBRX) stock price surged and what next

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. “The FDA's approval of ANKTIVA marks our launch of a next-generation immun.

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The U.S. Food and Drug Administration approved ImmunityBio's combination therapy to treat a type of bladder cancer, the regulator said on Monday, allowing the company's first product to market.

U.S. FDA approves ImmunityBio's bladder cancer therapy

Lemonade

Depending on who you ask,  a recession  is either right around the corner, or the stock market is ready to rattle off a seismic bull run.

2 Stocks Under $20: Immunitybio and Lemonade

Carvana

With the broader market reaching new all-time highs, primarily driven by the tech sector and specifically semiconductor stocks fueled by the hype surrounding AI, the spotlight is once again beginning to shine on high short-interest stocks.

5 Stocks with Unusually Large Short Interest

News for ImmunityBio Stock (IBRX)